Editorial: The ibd drug pipeline - Ready to deliver?

American Journal of Gastroenterology

Volumn 109, Issue 7, 2014, Pages 1053-1054

  Higgins, Peter D R ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFALIZUMAB; ETROLIZUMAB; INFLIXIMAB; NATALIZUMAB; PHOSPHATIDYLCHOLINE; TOFACITINIB; USTEKINUMAB; VEDOLIZUMAB;

CROHN DISEASE; DRUG APPROVAL; DRUG INDICATION; INFLAMMATORY BOWEL DISEASE; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS; FEMALE; HUMAN; MALE; NOTE;

COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; PHOSPHATIDYLCHOLINES;

EID: 84903845984     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.179     Document Type: Review

References (12)

1. Karner M, Kocjan A, Stein J et al. First Multicenter study of modif ed release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses. Am J Gastro-enterol 2014;109:1041-51 (this issue).
2. Ehehalt R, Wagenblast J, Erben G et al. Phosphatidylcholine and lysophos-phatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoElectrospray-tandem mass spectrometry. Scand J Gastroenterol 2004;39:737-42.
3. Walmsley RS, Ayres RC, Pounder RE et al. A simple clinical colitis activity index. Gut 1998;43:29-32.
4. FDAwebnewsreleaseon20May2014. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm398065.htm.
5. VanAssche G, VanRanst M, Sciot R et al. Progressive multifocal leukoen-cephalopathy af er natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-8.
6. Schwab N, Ulzheimer JC, Fox RJ et al. Fatal PML associated with efalizu-mab therapy: insights into integrin alphaLbeta2 in JC virus control. Neurology 2012;78:458-67.
7. Vermeire S, O'Byrne S, Keir M et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014.
8. Vermeire S, Ghosh S, Panes J et al. The mucosal addressin cell adhesion molecule antibody PF-00547, 659 in ulcerative colitis: a randomised study. Gut 2011;60:1068-75.
9. Takazoe M, Watanabe M, Kawaguchi T et al. Oral Alpha-4 Integrin Inhibitor (AJM300) in patients with active Crohn's Disease - a randomized, double-blind, placebo-controlled trial. Digestive Disease Week 2014 (abstract S1066).
10. Sandborn WJ, Gasink C, Gao LL et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367: 1519-28.
11. vanVollenhoven RF, Fleischmann R, Cohen S et al. Tofacitiniboradalimu-mab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-19.
12. VandeCasteele N, Compernolle G, Ballet V et al. Individualised inf iximab treatment using therapeutic drug monitoring: a prospective controlled Trough Level Adapted Inf iximab Treatment (TAXIT) trial. ECCO 2012, Oral Presentation 11.